Olivier Sitbon

List of Publications by Citations

295 papers	26,284 citations	74 h-index	158 g-index
377 ext. papers	31,669 ext. citations	8.1 avg, IF	6.5 L-index

#	Paper	IF	Citations
295	Pulmonary arterial hypertension in France: results from a national registry. *American Journal of Respiratory and Critical Care Medicine*, **2006**, 173, 1023-30	10.2	1367
294	Treatment of pulmonary arterial hypertension. *New England Journal of Medicine*, **2004**, 351, 1425-36	59.2	1338
293	Inhaled iloprost for severe pulmonary hypertension. *New England Journal of Medicine*, **2002**, 347, 322-9	59.2	1308
292	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet, The*, **2001**, 358, 1119-23	40	1175
291	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *Journal of the American College of Cardiology*, **2002**, 40, 780-8	15.1	1074
290	Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. *Circulation*, **2010**, 122, 156-63	16.7	1035
289	Macitentan and morbidity and mortality in pulmonary arterial hypertension. *New England Journal of Medicine*, **2013**, 369, 809-18	59.2	878
288	Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation*, **2005**, 111, 3105-11	16.7	815
287	Diagnosis and differential assessment of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2004**, 43, 40S-47S	15.1	651
286	Selexipag for the Treatment of Pulmonary Arterial Hypertension. *New England Journal of Medicine*, **2015**, 373, 2522-33	59.2	521
285	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. *Journal of the American College of Cardiology*, **2002**, 39, 1496-502	15.1	478
284	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. *European Respiratory Journal*, **2010**, 36, 549-55	13.6	456
283	Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation*, **2012**, 125, 2128-37	16.7	448
282	Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Annals of Internal Medicine*, **2008**, 149, 521-30	8	437
281	Updated evidence-based treatment algorithm in pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S78-S84	15.1	379
280	Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 108-13	10.2	324
279	Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. *Human Mutation*, **2006**, 27, 121-32	4.7	322

278	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	298
277	Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. *Arthritis and Rheumatism*, **2008**, 58, 521-31		261
276	EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. *Nature Genetics*, **2014**, 46, 65-9	36.3	259
275	Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. *Chest*, **2006**, 130, 182-9	5.3	254
274	Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1433-9	10.2	247
273	Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. *Gastroenterology*, **2006**, 130, 120-6	13.3	240
272	Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. *Anesthesiology*, **2005**, 102, 1133-7; discussion 5A-6A	4.3	234
271	Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. *Medicine (United States)*, **2008**, 87, 220-233	1.8	229
270	Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 177, 1377-83	10.2	225
269	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. *European Heart Journal*, **2006**, 27, 589-95	9.5	224
268	Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. *Chest*, **2003**, 124, 247-54	5.3	221
267	Pulmonary veno-occlusive disease. *European Respiratory Journal*, **2009**, 33, 189-200	13.6	216
266	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. *European Respiratory Journal*, **2014**, 43, 1691-7	13.6	214
265	Advances in therapeutic interventions for patients with pulmonary arterial hypertension. *Circulation*, **2014**, 130, 2189-208	16.7	209
264	Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 851-61	10.2	209
263	Treatment goals of pulmonary hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D73-81	15.1	207
262	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. *Lancet Respiratory Medicine,the*, **2016**, 4, 129-37	35.1	202
261	Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. *Arthritis and Rheumatism*, **2011**, 63, 3522-30		199

260	Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 170, 1212-7	10.2	192
259	Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. *American Journal of Roentgenology*, **2004**, 183, 65-70	5.4	190
258	International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. *Transplantation*, **2016**, 100, 1440-52	1.8	188
257	Severe pulmonary hypertension in histiocytosis X. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 161, 216-23	10.2	186
256	Portopulmonary hypertension: survival and prognostic factors. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 637-43	10.2	175
255	Pulmonary arterial hypertension. *Orphanet Journal of Rare Diseases*, **2013**, 8, 97	4.2	168
254	End points and clinical trial design in pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S97-S107	15.1	166
253	Criteria for diagnosis of exercise pulmonary hypertension. *European Respiratory Journal*, **2015**, 46, 728-37	13.6	154
252	Prostanoid therapy for pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2004**, 43, 56S-61S	15.1	154
251	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. *Journal of Clinical Investigation*, **2016**, 126, 3207-18	15.9	144
250	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. *European Heart Journal*, **2010**, 31, 1898-907	9.5	139
249	Pulmonary veno-occlusive disease. *European Respiratory Journal*, **2016**, 47, 1518-34	13.6	134
248	Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. *Clinics in Chest Medicine*, **2001**, 22, 451-8	5.3	132
247	Targeted therapies in pulmonary arterial hypertension. *Pharmacology & Therapeutics*, **2014**, 141, 172-91	13.9	128
246	Endothelin receptor antagonists in pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2004**, 43, 62S-67S	15.1	125
245	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. *Aids*, **2010**, 24, 67-75	3.5	118
244	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. *American Journal of Pathology*, **2015**, 185, 356-71	5.8	116
243	Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2007**, 26, 357-62	5.8	105

242	Treatment of pulmonary arterial hypertension with targeted therapies. *Nature Reviews Cardiology*, **2011**, 8, 526-38	14.8	102
241	Is pulmonary arterial hypertension really a late complication of systemic sclerosis?. *Chest*, **2009**, 136, 1211-1219	5.3	100
240	Risk factors for pulmonary arterial hypertension. *Clinics in Chest Medicine*, **2001**, 22, 459-75	5.3	94
239	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. *Circulation*, **2018**, 137, 693-704	16.7	92
238	Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. *Annals of the Rheumatic Diseases*, **2013**, 72, 1940-6	2.4	89
237	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. *Arthritis and Rheumatism*, **2011**, 63, 2456-64		87
236	Initial dual oral combination therapy in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 47, 1727-36	13.6	85
235	Pathways in pulmonary arterial hypertension: the future is here. *European Respiratory Review*, **2012**, 21, 321-7	9.8	83
234	Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. *European Respiratory Journal*, **2010**, 35, 1294-302	13.6	83
233	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	82
232	Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. *Arthritis and Rheumatism*, **2012**, 64, 2995-3005		82
231	Clinical trial design and new therapies for pulmonary arterial hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	81
230	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. *Circulation*, **2015**, 132, 834-47	16.7	80
229	Pulmonary veno-occlusive disease: recent progress and current challenges. *Respiratory Medicine*, **2010**, 104 Suppl 1, S23-32	4.6	78
228	Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 338-40	10.2	78
227	Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 162, 1493-9	10.2	78
226	Primary pulmonary hypertension associated with the use of fenfluramine derivatives. *Chest*, **1998**, 114, 195S-199S	5.3	77
225	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. *Lancet Respiratory Medicine,the*, **2017**, 5, 125-134	35.1	76

224	Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. *European Respiratory Journal*, **2014**, 43, 915-7	13.6	76
223	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. *European Respiratory Journal*, **2013**, 41, 96-103	13.6	75
222	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. *Advances in Therapy*, **2009**, 26, 813-25	4.1	75
221	Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. *Rheumatology*, **2010**, 49, 490-500	3.9	74
220	Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. *Circulation*, **1996**, 93, 484-8	16.7	74
219	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. *Journal of Heart and Lung Transplantation*, **2012**, 31, 150-8	5.8	73
218	Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. *Radiology*, **2002**, 222, 782-8	20.5	73
217	Treatment of pulmonary hypertension secondary to connective tissue diseases. *Thorax*, **1999**, 54, 273-7	7.3	72
216	ERS statement on chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2021**, 57,	13.6	70
215	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	69
214	Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. *European Respiratory Journal*, **2009**, 34, 1348-56	13.6	69
213	Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. *Journal of Cardiovascular Pharmacology*, **2007**, 49, 1-5	3.1	67
212	Pulmonary arterial hypertension in patients treated with interferon. *European Respiratory Journal*, **2014**, 44, 1627-34	13.6	66
211	Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. *Respiratory Research*, **2010**, 11, 73	7.3	66
210	Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. *European Respiratory Journal*, **2013**, 41, 578-87	13.6	65
209	Genetic counselling in a national referral centre for pulmonary hypertension. *European Respiratory Journal*, **2016**, 47, 541-52	13.6	63
208	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 717-726	35.1	62
207	Validation of two predictive models for survival in pulmonary arterial hypertension. *European Respiratory Journal*, **2015**, 46, 152-64	13.6	62

206	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. *European Respiratory Journal*, **2017**, 50,	13.6	62
205	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. *Lancet Respiratory Medicine,the*, **2019**, 7, 594-604	35.1	61
204	Pulmonary hypertension associated with benfluorex exposure. *European Respiratory Journal*, **2012**, 40, 1164-72	13.6	60
203	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	58
202	Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. *Circulation*, **2000**, 102, 2460-2	16.7	58
201	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. *European Respiratory Journal*, **2020**, 56,	13.6	57
200	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. *European Respiratory Journal*, **2015**, 46, 1721-31	13.6	55
199	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238	35.1	55
198	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. *Journal of the American College of Cardiology*, **2018**, 71, 752-763	15.1	50
197	Pulmonary vascular abnormalities in cirrhosis. *Baillierek's Best Practice and Research in Clinical Gastroenterology*, **2007**, 21, 141-59	2.5	49
196	BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1668-1681	13.6	49
195	Primary pulmonary hypertension: Current therapy. *Progress in Cardiovascular Diseases*, **2002**, 45, 115-28	8.5	48
194	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. *Chest*, **2016**, 149, 353-361	5.3	46
193	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. *American Heart Journal*, **2014**, 167, 210-7	4.9	46
192	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. *European Heart Journal*, **2017**, 38, 1147-1155	9.5	44
191	Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. *Rheumatology*, **2010**, 49, 940-4	3.9	44
190	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. *JACC: Heart Failure*, **2015**, 3, 1-8	7.9	42
189	Pulmonary hypertension in patients with neurofibromatosis type I. *Medicine (United States)*, **2011**, 90, 201-211	1.8	42

188	Current and future treatments of pulmonary arterial hypertension. *British Journal of Pharmacology*, **2021**, 178, 6-30	8.6	42
187	Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension. *European Respiratory Journal*, **2014**, 44, 704-13	13.6	41
186	Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. *Circulation*, **2010**, 122, 1937-47	16.7	41
185	Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. *European Respiratory Review*, **2017**, 26,	9.8	40
184	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. *Hepatology*, **2017**, 65, 1683-1692	11.2	40
183	Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. *Chest*, **2012**, 142, 869-876	5.3	40
182	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. *American Journal of Cardiovascular Drugs*, **2018**, 18, 37-47	4	39
181	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. *European Respiratory Journal*, **2012**, 40, 75-83	13.6	39
180	Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. *Chest*, **2010**, 137, 1297-303	5.3	38
179	Beyond a single pathway: combination therapy in pulmonary arterial hypertension. *European Respiratory Review*, **2016**, 25, 408-417	9.8	38
178	Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman disease. *European Respiratory Journal*, **2005**, 26, 969-72	13.6	37
177	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. *European Respiratory Journal*, **2018**, 52,	13.6	37
176	Macitentan Improves Health-Related Quality´of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. *Chest*, **2017**, 151, 106-118	5.3	36
175	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. *European Respiratory Journal*, **2016**, 48, 1517-1519	13.6	36
174	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. *Chest*, **2018**, 153, 143-151	5.3	35
173	Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. *Presse Medicale*, **2014**, 43, e345-63	2.2	34
172	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. *Chest*, **2016**, 149, 1482-93	5.3	33
171	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. *European Respiratory Journal*, **2014**, 44, 1069-72	13.6	33

170	Hemodynamics in pulmonary arterial hypertension: current and future perspectives. *American Journal of Cardiology*, **2012**, 110, 9S-15S	3	33
169	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2019**, 38, 833-842	5.8	32
168	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. *Circulation*, **2019**, 139, 2440-2450	16.7	32
167	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. *Medicine (United States)*, **2015**, 94, e1800	1.8	32
166	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. *Archives of Cardiovascular Diseases*, **2017**, 110, 303-316	2.7	31
165	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. *Journal of Heart and Lung Transplantation*, **2018**, 37, 647-655	5.8	31
164	Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics. *European Respiratory Journal*, **2016**, 47, 1436-44	13.6	31
163	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. *European Respiratory Journal*, **2015**, 46, 1711-20	13.6	31
162	Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension. *European Respiratory Journal*, **2015**, 45, 1495-8	13.6	31
161	Automatic quantification of right ventricular function with gated blood pool SPECT. *Journal of Nuclear Cardiology*, **2004**, 11, 293-304	2.1	31
160	Systolic and mean pulmonary artery pressures: are they interchangeable in patients with pulmonary hypertension?. *Chest*, **2015**, 147, 943-950	5.3	30
159	Therapeutic advances in pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2008**, 2, 249-65	4.9	30
158	Portopulmonary hypertension in the current era of pulmonary hypertension management. *Journal of Hepatology*, **2020**, 73, 130-139	13.4	28
157	Acute decompensated pulmonary hypertension. *European Respiratory Review*, **2017**, 26,	9.8	28
156	Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. *Seminars in Respiratory and Critical Care Medicine*, **2009**, 30, 411-20	3.9	28
155	The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 860-868	10.2	27
154	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. *Drug Safety*, **2016**, 39, 287-94	5.1	26
153	Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. *Chest*, **2015**, 147, 1385-1394	5.3	26

152	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. *European Journal of Heart Failure*, **2019**, 21, 352-359	12.3	26
151	Gut-Lung Connection in Pulmonary Arterial Hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2017**, 56, 402-405	5.7	25
150	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2017**, 36, 1234-1242	5.8	25
149	Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. *Aids*, **2005**, 19, 1239-40	3.5	25
148	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. *International Journal of Cardiology*, **2014**, 172, 561-7	3.2	24
147	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. *PLoS ONE*, **2018**, 13, e0197112	3.7	24
146	HIV-related pulmonary arterial hypertension: clinical presentation and management. *Aids*, **2008**, 22 Suppl 3, S55-62	3.5	23
145	Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature. *Medicine (United States)*, **2016**, 95, e4911	1.8	23
144	Interferon-induced pulmonary hypertension: an update. *Current Opinion in Pulmonary Medicine*, **2016**, 22, 415-20	3	23
143	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. *Lung*, **2018**, 196, 157-164	2.9	22
142	Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. *European Respiratory Journal*, **2009**, 34, 1204-6	13.6	22
141	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. *European Respiratory Journal*, **2021**, 58,	13.6	22
140	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. *Chest*, **2018**, 154, 872-881	5.3	22
139	Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?. *Presse Medicale*, **2011**, 40, e65-78	2.2	21
138	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. *Current Therapeutic Research*, **2002**, 63, 227-246	2.4	21
137	Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. *American Journal of Cardiovascular Drugs*, **2015**, 15, 13-26	4	19
136	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. *Journal of Heart and Lung Transplantation*, **2020**, 39, 300-309	5.8	19
135	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. *Expert Opinion on Drug Metabolism and Toxicology*, **2013**, 9, 1193-205	5.5	19

134	Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. *Respiration*, **2013**, 85, 471-7	3.7	19
133	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 1585-96	4	19
132	Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. *Chest*, **2005**, 128, 622S	5.3	19
131	Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. *Chest*, **2013**, 144, 1512-1520	5.3	18
130	Pulmonary hypertension associated with neurofibromatosis type 1. *European Respiratory Review*, **2018**, 27,	9.8	18
129	New pharmacotherapy options for pulmonary arterial hypertension. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 2113-31	4	17
128	Exertional dyspnoea in pulmonary arterial hypertension. *European Respiratory Review*, **2017**, 26,	9.8	17
127	Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. *European Respiratory Review*, **2009**, 18, 272-90	9.8	17
126	The association between resting and mild-to-moderate exercise pulmonary artery pressure. *European Respiratory Journal*, **2012**, 39, 313-8	13.6	17
125	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. *PLoS ONE*, **2018**, 13, e0193226	3.7	17
124	Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. *European Respiratory Journal*, **2016**, 48, 254-7	13.6	17
123	Portopulmonary Hypertension. *Seminars in Respiratory and Critical Care Medicine*, **2017**, 38, 651-661	3.9	16
122	Pulmonary arterial hypertension and HIV infection. *Seminars in Respiratory and Critical Care Medicine*, **2009**, 30, 440-7	3.9	16
121	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. *European Respiratory Journal*, **2020**, 55,	13.6	16
120	Factors predicting outcome after pulmonary endarterectomy. *PLoS ONE*, **2018**, 13, e0198198	3.7	16
119	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. *Journal of the American College of Cardiology*, **2021**, 78, 1393-1403	15.1	16
118	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. *Annals of Thoracic Surgery*, **2017**, 104, 404-411	2.7	15
117	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. *Journal of Heart and Lung Transplantation*, **2018**, 37, 1102-1110	5.8	15

116	Chronic thromboembolic pulmonary hypertension. *Presse Medicale*, **2015**, 44, e409-16	2.2	15
115	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. *European Respiratory Journal*, **2018**, 52,	13.6	15
114	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. *American Journal of Pathology*, **2019**, 189, 1159-1175	5.8	14
113	Risk assessment in pulmonary arterial hypertension. *European Respiratory Journal*, **2018**, 51,	13.6	14
112	PatientsQrelativesQand practitionersQviews of pulmonary arterial hypertension: A qualitative study. *Presse Medicale*, **2016**, 45, e11-27	2.2	14
111	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. *Journal of Cardiac Failure*, **2017**, 23, 29-35	3.3	14
110	Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2014**, 33, 689-97	5.8	14
109	The study of risk in pulmonary arterial hypertension. *European Respiratory Review*, **2012**, 21, 234-8	9.8	14
108	Pharmacokinetic evaluation of continuous intravenous epoprostenol. *Expert Opinion on Drug Metabolism and Toxicology*, **2010**, 6, 1587-98	5.5	14
107	Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial. *Chest*, **2012**, 142, 1026A	5.3	14
106	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. *Chest*, **2020**, 157, 955-965	5.3	14
105	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 842-854	10.2	13
104	Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. *Chest*, **2019**, 155, 991-998	5.3	12
103	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. *European Respiratory Journal*, **2020**, 56,	13.6	12
102	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. *Journal of Heart and Lung Transplantation*, **2018**, 37, 401-408	5.8	12
101	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. *Journal of Heart and Lung Transplantation*, **2017**, 36, 386-398	5.8	12
100	Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure. *Respiration*, **2013**, 85, 464-70	3.7	12
99	Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. *Expert Opinion on Pharmacotherapy*, **2005**, 6, 1337-48	4	12

98	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. *European Respiratory Journal*, **2020**, 56,	13.6	11
97	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. *European Respiratory Journal*, **2020**, 55,	13.6	11
96	Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension. *Seminars in Respiratory and Critical Care Medicine*, **2013**, 34, 645-53	3.9	11
95	Screening for pulmonary arterial hypertension in adults carrying a mutation. *European Respiratory Journal*, **2021**, 58,	13.6	11
94	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. *Chest*, **2016**, 150, 256-8	5.3	11
93	Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension. *PLoS ONE*, **2015**, 10, e0134221	3.7	10
92	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2021**, 178, 106220	4.6	10
91	A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. *Annals of the Rheumatic Diseases*, **2016**, 75, 1457-65	2.4	9
90	Pulmonary arterial hypertension in patients treated with interferon. *European Respiratory Journal*, **2015**, 46, 1851-3	13.6	9
89	Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. *Respiratory Medicine*, **2010**, 104 Suppl 1, S74-80	4.6	9
88	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism. *European Respiratory Journal*, **2012**, 39, 1549-50	13.6	9
87	Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. *Journal of Heart and Lung Transplantation*, **2017**, 36, 399-406	5.8	8
86	Risk stratification in pulmonary arterial hypertension. *Current Opinion in Pulmonary Medicine*, **2018**, 24, 407-415	3	8
85	Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. *European Respiratory Journal*, **2014**, 43, 641-3	13.6	8
84	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. *European Respiratory Journal*, **2019**, 54,	13.6	8
83	Pulmonary hypertension due to left heart disease. *Archives of Cardiovascular Diseases*, **2017**, 110, 420-431	1.7	7
82	Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis. *Liver Transplantation*, **2020**, 26, 935-940	4.5	7
81	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. *Respiration*, **2018**, 95, 244-250	3.7	7

80	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. *Chest*, **2018**, 154, 882-892	5.3	7
79	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2014**, 8, 84-92	4.9	7
78	Pulmonary venoocclusive disease and failure of specific therapy. *Chest*, **2009**, 136, 1181; author reply 1181-2	5.3	7
77	Riociguat: Clinical research and evolving role in therapy. *British Journal of Clinical Pharmacology*, **2021**, 87, 2645-2662	3.8	7
76	Idiopathic pulmonary hypertension: what did we learn from genes?. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2005**, 22 Suppl 1, S91-100	1.1	7
75	Medical Treatment of Pulmonary Arterial Hypertension. *Seminars in Respiratory and Critical Care Medicine*, **2017**, 38, 686-700	3.9	6
74	Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution. *European Respiratory Journal*, **2020**, 55,	13.6	6
73	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. *European Respiratory Review*, **2016**, 25, 93-6	9.8	6
72	Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. *Chest*, **2011**, 140, 1066-1068	5.3	6
71	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. *Archivos De Bronconeumologia*, **2020**, 56, 578-585	0.7	6
70	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2016**, 35, 647-56	5.8	6
69	Serum and pulmonary uric acid in pulmonary arterial hypertension. *European Respiratory Journal*, **2021**, 58,	13.6	6
68	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e005095	5.8	5
67	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. *Canadian Journal of Cardiology*, **2015**, 31, 1469-76	3.8	5
66	Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 537-541	10.2	5
65	Mediastinal fibrosis mimicking proximal chronic thromboembolic disease. *Circulation*, **2012**, 125, 2045-7	16.7	5
64	Calcium-channel blockers in pulmonary arterial hypertension. *Handbook of Experimental Pharmacology*, **2013**, 218, 161-75	3.2	5
63	Calcium-Channel Blockers in Pulmonary Arterial Hypertension. *Handbook of Experimental Pharmacology*, **2013**, 161-175	3.2	5

62	Survival Improved in Patients Aged ⩾70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. *Chest*, **2020**, 157, 945-954	5.3	5
61	Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension. *BioMed Research International*, **2016**, 2016, 6050193	3	5
60	Management of pulmonary arterial hypertension in patients aged over 65 years. *European Heart Journal Supplements*, **2019**, 21, K29-K36	1.5	5
59	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. *Chest*, **2021**, 159, 1197-1207	5.3	5
58	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 843-852	10.2	4
57	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. *Advances in Therapy*, **2021**, 39, 796	4.1	4
56	External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. *European Respiratory Journal*, **2021**,	13.6	4
55	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. *Pulmonary Circulation*, **2020**, 10, 2045894020962960	2.7	4
54	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". *Circulation*, **2016**, 133, e592-3	16.7	4
53	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2020**, 177, 106241	4.6	4
52	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. *Chest*, **2021**, 160, 277-286	5.3	4
51	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. *International Journal of Clinical Pharmacy*, **2018**, 40, 790-794	2.3	3
50	Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). *Chest*, **2015**, 148, 961A	5.3	3
49	Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study. *Journal of Clinical Monitoring and Computing*, **2017**, 31, 903-910	2	3
48	Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. *European Respiratory Journal*, **2015**, 46, 1211-4	13.6	3
47	Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". *Circulation*, **2015**, 132, e154	16.7	3
46	Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment. *European Respiratory Review*, **2014**, 23, 505-9	9.8	3
45	Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. *Chest*, **2013**, 144, 876A	5.3	3

44	Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice. *Current Opinion in Pulmonary Medicine*, **2010**, 16 Suppl 1, S21-6	3	3
43	Bosentan therapy for pulmonary arterial hypertension. *Future Cardiology*, **2005**, 1, 299-309	1.3	3
42	Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) **2018**,		3
41	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. *Pulmonary Circulation*, **2021**, 11, 20458940211057071	2.7	3
40	French recommendations for the management of systemic sclerosis. *Orphanet Journal of Rare Diseases*, **2021**, 16, 322	4.2	3
39	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. *European Respiratory Journal*, **2021**, 57,	13.6	3
38	Six-Years Experience With High Priority Allocation Program for Lung and Heart-Lung Transplantation in Pulmonary Hypertension. *Journal of Heart and Lung Transplantation*, **2015**, 34, S160	5.8	2
37	Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. *Clinics and Research in Hepatology and Gastroenterology*, **2020**, 44, 426-432	2.4	2
36	Are indexed values better for defining exercise pulmonary hypertension?. *European Respiratory Journal*, **2017**, 50,	13.6	2
35	Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 378-379	10.2	2
34	Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal. *European Respiratory Review*, **2012**, 21, 259-62	9.8	2
33	The dangerous and contradictory prognostic significance of PVR. *ESC Heart Failure*, **2020**, 7, 2398-2405	3.7	2
32	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. *European Respiratory Journal*, **2021**, 58,	13.6	2
31	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. *Journal of Clinical Immunology*, **2021**, 41, 1549-1562	5.7	2
30	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	2
29	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. *International Journal of Cardiology*, **2015**, 184, 763-765	3.2	1
28	Pulmonary Arterial Hypertension and HIV and Other Viral Infections. *Progress in Respiratory Research*, **2012**, 105-112		1
27	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. *European Journal of Heart Failure*, **2021**,	12.3	1

26	Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. *Respiratory Medicine*, **2020**, 79-96	0.2	1
25	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. *British Journal of Anaesthesia*, **2020**, 125, e466-e468	5.4	1
24	Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension. *Respiration*, **2020**, 99, 678-685	3.7	1
23	The isobaric pulmonary arterial compliance in pulmonary hypertension. *ERJ Open Research*, **2021**, 7,	3.5	1
22	Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. *Pulmonary Circulation*, **2021**, 11, 2045894021996930	2.7	1
21	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. *European Respiratory Journal*, **2021**, 58,	13.6	1
20	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. *Journal of Heart and Lung Transplantation*, **2021**, 40, 1009-1018	5.8	1
19	Pulmonary hypertension associated with busulfan. *Pulmonary Circulation*, **2021**, 11, 20458940211030170	2.7	1
18	Assembly 13: placing the pulmonary circulation in the heart of ERS. *Breathe*, **2019**, 15, 88-89	1.8	0
17	Outcome of Portopulmonary Hypertension After Liver Transplantation: Perhaps Not So Optimistic. *Transplantation*, **2018**, 102, e190-e191	1.8	0
16	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. *International Journal of Clinical Pharmacy*, **2020**, 42, 1128-1138	2.3	0
15	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. *Archivos De Bronconeumologia*, **2020**, 56, 578-585	0.7	0
14	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pi□e de R§istance?. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 524-525	10.2	0
13	Association between Leflunomide and Pulmonary Hypertension. *Annals of the American Thoracic Society*, **2021**, 18, 1306-1315	4.7	0
12	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. *Frontiers in Medicine*, **2022**, 9, 851935	4.9	0
11	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. *ERJ Open Research*, **2022**, 8, 00665-2021	3.5	0
10	Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, e90-e91	10.2	
9	Portopulmonary Hypertension and Hepatopulmonary Syndrome. *Progress in Respiratory Research*, **2012**, 113-121		

8	Right heart failure32-47	
7	Pulmonary hypertension associated with portal hypertension **2011**, 245-250	
6	Pulmonary hypertension related to appetite suppressants **2011**, 236-244	
5	Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?". *Journal of Hepatology*, **2021**, 74, 238-239	13.4
4	Reversible pulmonary hypertension associated with multivisceral Whipple disease. *European Respiratory Journal*, **2021**, 57,	13.6
3	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers.. *Pulmonary Circulation*, **2022**, 12, e12023	2.7
2	ERS statement on chronic thromboembolic pulmonary hypertension. *Pulmonologiya*, **2022**, 32, 13-52	0.8
1	To be or not to be treated with initial combination therapy, that is the (PAH) question. *European Respiratory Journal*, **2022**, 59, 2200390	13.6